Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 9/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7973475 | 0.84 | ATM (0.46) | VCAM1MAPK1ALDH1A1KDM4EHTT | |
| SCHEMBL7545601 | 0.82 | ALDH3A1 (0.46) | VCAM1TSHRMAPK1SLC6A4ALDH1A1 | |
| SCHEMBL2477068 | 0.79 | TSHR (0.52) | VCAM1TSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL29653309 | 0.79 | TSHR (0.52) | VCAM1TSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL3543539 | 0.77 | TSHR (0.50) | VCAM1TSHRMAPK1SLC6A4ALDH1A1 | |
| SCHEMBL30110338 | 0.77 | TSHR (0.50) | VCAM1TSHRMAPK1SLC6A4ALDH1A1 | |
| SCHEMBL12919852 | 0.77 | PDK1 (0.39) | VCAM1MAPK1ALDH1A1CYP3A4KDM4E | |
| SCHEMBL7976359 | 0.77 | TDP1 (0.42) | ALDH1A1CYP3A4KDM4EHTTHCAR3 | |
| SCHEMBL29559612 | 0.76 | MAPT (0.45) | VCAM1MAPK1ALDH1A1CYP3A4KDM4E | |
| SCHEMBL31423821 | 0.76 | ALDH1A1 (0.51) | TSHRMAPK1ALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067658-B2 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004031189-A1 | PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | CRHR1, CRHR2, CRH | VCAM1 3527/4885TSHR 90/4885MAPK1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.